Kynurenic acid is a product of the normal metabolism of amino acid L-tryptophan. It has been shown that kynurenic acid possesses neuroactive activity. It acts as an antiexcitotoxic and anticonvulsant, most likely through acting as an antagonist at excitatory amino acid receptors; pharmacologically it antagonizes the NMDA receptor at the glycine co-agonist site and inhibits alpha7 nicotinic acetylcholine receptors, with additional weaker effects on AMPA and kainate receptor subtypes at higher concentrations. Chemically, kynurenic acid is 4-hydroxyquinoline-2-carboxylic acid with a molecular weight of 189.17 g mol and a planar heteroaromatic scaffold that confers limited aqueous solubility at neutral pH but good solubility in polar aprotic solvents and alkaline media. In biology it is formed predominantly from L-kynurenine via kynurenine aminotransferases in glial cells, shows low passive blood brain barrier permeability so local production in brain is important, and it is typically handled and assayed by HPLC or LC MS methods; typical laboratory handling calls for storage protected from light at refrigerated temperatures and formulation considerations for in vitro work include dissolution in DMSO or alkaline buffers to ensure reproducible dosing.
Parent: Kynurenic Acid
Typical product specification for kynurenic acid used in research and formulation lists assay purity greater than or equal to 98.0 percent by HPLC, water content less than or equal to 0.5 percent by Karl Fischer, residual solvent content below 0.5 percent w w by GC, and total heavy metals below 10 parts per million by ICP MS; specified related substances and typical acceptance limits include L kynurenine not greater than 0.5 percent, 3 hydroxykynurenine not greater than 0.2 percent, anthranilic acid not greater than 0.2 percent, xanthurenic acid not greater than 0.2 percent with total related compounds not exceeding 1.0 percent, and unspecified impurities each below 0.1 percent. Analytical methods normally cited for these limits are reversed phase HPLC with UV detection for assay and related substances, GC for residual solvents, and elemental analysis or ICP MS for trace metals.
Kynurenic acid is an endogenous metabolite in the tryptophan kynurenine pathway produced from L kynurenine by kynurenine aminotransferases; it is a small heteroaromatic acid that modulates neurotransmission by antagonizing NMDA receptor glycine sites and alpha7 nicotinic receptors and is commonly measured by HPLC or LC MS in biological samples.
Alterations in the kynurenine pathway, including regional changes in kynurenic acid levels, have been reported in Alzheimer disease research; elevated kynurenic acid may reflect increased kynurenine pathway activity in glia and can have dual implications by reducing excitotoxic damage but also by antagonizing receptors involved in synaptic plasticity, so its role in disease is context dependent and an active area of investigation rather than a single diagnostic marker.
High kynurenic acid concentrations indicate upregulation of kynurenine pathway metabolism, often due to increased conversion of kynurenine in glial cells or peripheral inflammation driving pathway flux; physiologically this can reduce excitotoxic neurotransmission but may also dampen cholinergic and glutamatergic signaling, with potential functional consequences that depend on tissue, timing, and the balance of other pathway metabolites.
Kynurenic acid is generally considered neuroprotective against excitotoxic injury because it antagonizes excitatory amino acid receptors, but at the same time excessive kynurenic acid can impair normal synaptic signaling and cognitive processes; it is not classically neurotoxic like quinolinic acid, though its net effect on neuronal function depends on concentration, cellular context, and the presence of other metabolites.
